Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Biology

Biochemistry

Chemistry

Medicine

Epidemiology

Show all topics

DOI

10.1016/s0140-6736(06)68439-0